CD22 Lentivirus

Products from BPS Bioscience require a minimum order value above 400€

Applications: Study the transient expression of human CD22 in target cells.Generate a stable cell line expressing human CD22 with limiting dilution and puromycin selection.

Background: CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It acts as an inhibitory co-receptor of the B-cell receptor to control the B-cell immune response. In 2017 the FDA approved Besponsa, an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.

Description: The CD22 Lentiviruses are replication incompetent, HIV based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express human CD22 (NM_001771) under the control of an EF1a promoter.

Formulation: The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS.

Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥10⁷ TU/ml. The titer will vary with each lot; the exact value will be provided with each shipment.

Warnings: Avoid freeze/thaw cycles.

Biosafety Level: BSL-2

• Artikelnummer: BPS78659
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 78659
• Verpackungseinheit: 500 µl x 2
• Mengeneinheit: STK